Top

BMC Cancer

Published in:

Open Access 01-12-2018 | Study protocol

‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment

Authors: J. Rotman, C. H. Mom, E. S. Jordanova, T. D. de Gruijl, G. G. Kenter

Published in: BMC Cancer | Issue 1/2018

Abstract

Background

Treatment with programmed cell death receptor (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors is a promising strategy to lift tumour-induced immune response suppression. However, the current systemic treatment often causes autoimmune side effects. In more than 50% of squamous cell cervical cancer, PD-L1 expression is detected. Moreover, we observed high and interrelated rates of PD-L1 positive macrophages and regulatory T cells in metastatic lymph nodes of cervical cancer patients. As cervical cancer in general initially metastasizes to regional lymph nodes, local administration of durvalumab (a PD-L1 checkpoint inhibitor) at an early stage will deliver these antibodies exactly where they are needed, facilitating immune protection. This may result in a clinical benefit while reducing undesirable side effects.

Methods

DURVIT is a non-randomized, single-arm, open-label, phase I study. Three escalating dose levels of intratumourally (i.t.) injected durvalumab will be tested, i.e. 5, 10 and 20 mg (three patients per dose level, with an additional three at the highest tolerated dose). The primary endpoint of this phase-I study is safety. Immune monitoring will consist of flow cytometric, immunohistochemical and functional T cell reactivity testing. The first patient has been included in this trial in November 2017.

Discussion

Evidence of safety and biological efficacy of this locally administered checkpoint blockade may expand adjuvant therapy options for cervical cancer patients. Early metastatic spread of cervical cancer cells may thus be controlled in the draining lymph node basin, and beyond, and hopefully delay or even prevent the onset of disease recurrence.

Trial registration

NTR6119, 1-nov-2016.

Available only for authorised users

Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24(Suppl. 1):4–15.CrossRef

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. https://doi.org/10.1002/ijc.29210.CrossRefPubMed

Integraal Kankercentrum Nederland: IKNL. http://www.cijfersoverkanker.nl (2011–2017). Accessed 6 Sept 2017.

Maine D, Hurlburt S, Greeson D. Cervical Cancer prevention in the 21st century: cost is not the only issue. Am J Public Health. 2011;101:1549–55. https://doi.org/10.2105/AJPH.2011.300204.CrossRefPubMedPubMedCentral

Takeda N, Sakuragi N, Takeda M, Okamoto K, Kuwabara M, Negishi H, et al. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet Gynecol Scand. 2002;81:1144–51. https://doi.org/10.1034/j.1600-0412.2002.811208.x.CrossRefPubMed

Lee YN, Wang KL, Lin MH, Liu CH, Wang KG, Lan CC, et al. Radical hysterectomy with pelvic lymph node dissection for treatment of cervical cancer: a clinical review of 954 cases. Gynecol Oncol. 1989;32:135–42. doi:S0090-8258(89)80024-1CrossRefPubMed

Chen Y, Zhang L, Tian J, Fu X, Ren X, Hao Q. Significance of the absolute number and ratio of metastatic lymph nodes in predicting postoperative survival for the International Federation of Gynecology and Obstetrics Stage IA2 to IIA cervical Cancer. Int J Gynecol Cancer. 2013;23:157–63. https://doi.org/10.1097/IGC.0b013e3182778bcf.CrossRefPubMed

Peters WA, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage Cancer of the cervix. J Clin Oncol. 2000;18:1606–13. https://doi.org/10.1200/JCO.2000.18.8.1606.CrossRefPubMed

Monk BJ, Wang J, Im S, Stock RJ, Peters WA, Liu PY, et al. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical–pathologic analysis of a gynecologic oncology group/southwest oncology group/radiation therapy oncology group trial. Gynecol Oncol. 2005;96:721–8. https://doi.org/10.1016/j.ygyno.2004.11.007.CrossRefPubMed

10.

Greimel ER, Winter R, Kapp KS, Haas J. Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study. Psychooncology. 2009;18:476–82. https://doi.org/10.1002/pon.1426.CrossRefPubMed

11.

Moss EL, Taneja S, Munir F, Kent C, Robinson L, Potdar N, et al. Iatrogenic menopause after treatment for cervical Cancer. Clin Oncol. 2016;28:766–75. https://doi.org/10.1016/j.clon.2016.08.016.CrossRef

12.

Mu C-Y, Huang J-A, Chen Y, Chen C, Zhang X-G. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28:682–8. https://doi.org/10.1007/s12032-010-9515-2.CrossRefPubMed

13.

Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer. 2005;104:2084–91. https://doi.org/10.1002/cncr.21470.CrossRefPubMed

14.

Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66:3381–5. https://doi.org/10.1158/0008-5472.CAN-05-4303.CrossRefPubMed

15.

Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, Leibovich BC, et al. Survivin and B7-H1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res. 2007;13:1749–56. https://doi.org/10.1158/1078-0432.CCR-06-2129.CrossRefPubMed

16.

Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13:2151–7. https://doi.org/10.1158/1078-0432.CCR-06-2746.CrossRefPubMed

17.

Loos M, Giese NA, Kleeff J, Giese T, Gaida MM, Bergmann F, et al. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett. 2008;268:98–109. https://doi.org/10.1016/j.canlet.2008.03.056.CrossRefPubMed

18.

Wang L, Ma Q, Chen X, Guo K, Li J, Zhang M. Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma. World J Surg. 2010;34:1059–65. https://doi.org/10.1007/s00268-010-0448-x.CrossRefPubMed

19.

Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104:3360–5. https://doi.org/10.1073/pnas.0611533104.CrossRefPubMedPubMedCentral

20.

Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17:4232–44. https://doi.org/10.1158/1078-0432.CCR-10-2660.CrossRefPubMed

21.

Brusa D, Serra S, Coscia M, Rossi D, D’Arena G, Laurenti L, et al. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013;98:953–63. https://doi.org/10.3324/haematol.2012.077537.CrossRefPubMedPubMedCentral

22.

Mezache L, Paniccia B, Nyinawabera A, Nuovo GJ. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol. 2015;28:1594–602. https://doi.org/10.1038/modpathol.2015.108.CrossRefPubMed

23.

Yang W, Lu Y-P, Yang Y-Z, Kang J-R, Jin Y-D, Wang H-W. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status. J Obstet Gynaecol Res. 2017; https://doi.org/10.1111/jog.13411.

24.

Reddy OL, Shintaku PI, Moatamed NA. Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas. Diagn Pathol. 2017;12:45. https://doi.org/10.1186/s13000-017-0631-6.CrossRefPubMedPubMedCentral

25.

Howitt BE, Sun HH, Roemer MGM, Kelley A, Chapuy B, Aviki E, et al. Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva. JAMA Oncol. 2016;2:518. https://doi.org/10.1001/jamaoncol.2015.6326.CrossRefPubMed

26.

Heeren AM, Punt S, Bleeker MC, Gaarenstroom KN, van der Velden J, Kenter GG, et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol. 2016;29:753–63. https://doi.org/10.1038/modpathol.2016.64.CrossRefPubMedPubMedCentral

27.

Heeren AM, Koster BD, Samuels S, Ferns DM, Chondronasiou D, Kenter GG, et al. High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical Cancer. Cancer Immunol Res. 2015;3:48–58. https://doi.org/10.1158/2326-6066.CIR-14-0149.CrossRefPubMed

28.

Heeren AM, de Boer E, Bleeker MCG, Musters RJP, Buist MR, Kenter GG, et al. Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area. Oncotarget. 2015;6:32484–93. https://doi.org/10.18632/oncotarget.5398.CrossRefPubMedPubMedCentral

29.

Heeren AM, Kenter GG, Jordanova ES, de Gruijl TD. CD14(+) macrophage-like cells as the linchpin of cervical cancer perpetrated immune suppression and early metastatic spread: a new therapeutic lead? Oncoimmunology. 2015;4:e1009296. https://doi.org/10.1080/2162402X.2015.1009296.CrossRefPubMedPubMedCentral

30.

Syed YY. Durvalumab: First Global Approval. Drugs. 2017;77:1369–76. https://doi.org/10.1007/s40265-017-0782-5.CrossRefPubMedPubMedCentral

31.

Imfinzi™ (durvalumab): US prescribing information. 2017. https://www.fda.gov. Accessed 26 Sep 2017.

32.

Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375–91. https://doi.org/10.1093/annonc/mdv383.

33.

Hesselink AT, Berkhof J, Van Der Salm ML, Van Splunter AP, Geelen TH, Van Kemenade FJ, et al. Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region. J Clin Microbiol. 2014;52:890–6.CrossRefPubMedPubMedCentral

34.

Buist MR, Pijpers RJ, van Lingen A, van Diest PJ, Dijkstra J, Kenemans P, et al. Laparoscopic detection of sentinel lymph nodes followed by lymph node dissection in patients with early stage cervical cancer. Gynecol Oncol. 2003;90:290–6. https://doi.org/10.1016/S0090-8258(03)00277-4.CrossRefPubMed

35.

Quinn M, Benedet J, Odicino F, Maisonneuve P, Beller U, Creasman W, et al. Carcinoma of the cervix uteri. Int J Gynecol Obstet. 2006;95:S43–103. https://doi.org/10.1016/S0020-7292(06)60030-1.CrossRef

36.

Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer. 2012;132:854–67.CrossRefPubMed

37.

Bulk S, Berkhof J, Bulkmans NWJ, Zielinski GD, Rozendaal L, Van Kemenade FJ, et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in the Netherlands. Br J Cancer. 2006;94:171–5.CrossRefPubMedPubMedCentral

38.

Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–48. https://doi.org/10.1016/j.ejca.2015.11.016.CrossRefPubMed

39.

Powles T, O’Donnell PH, Massard C, Arkenau H-T, Friedlander TW, Hoimes CJ, et al. Efficacy and safety of Durvalumab in locally advanced or metastatic urothelial carcinoma. JAMA Oncol. 2017;3:e172411. https://doi.org/10.1001/jamaoncol.2017.2411.CrossRefPubMedPubMedCentral

40.

Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti–PD-L1 antibody in patients with advanced Cancer. N Engl J Med. 2012;366:2455–65. https://doi.org/10.1056/NEJMoa1200694.CrossRefPubMedPubMedCentral

41.

Frenel J, Le Tourneau C, O’Neil B, Ott P, Piha-Paul S, Gomez-Roca C, Van Brummelen ERH. Pembrolizumab in patients with advanced cervical squamous cell cancer. J Clin Oncol. 2016;34:(suppl; abstr 5515)

42.

ClinicalTrials.gov. 2000. https://www.clinicaltrials.gov. Accessed 15 Sep 2017.

43.

Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RHI, et al. A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget. 2016;7:64390–9. https://doi.org/10.18632/oncotarget.10453.PubMedPubMedCentralCrossRef

44.

Molenkamp BG, Sluijter BJR, van Leeuwen PAM, Santegoets SJAM, Meijer S, Wijnands PGJTB, et al. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res. 2008;14:4532–42. https://doi.org/10.1158/1078-0432.CCR-07-4711.CrossRefPubMed

45.

Sluijter BJR, van den Hout MFCM, Koster BD, van Leeuwen PAM, Schneiders FL, van de Ven R, et al. Arming the melanoma sentinel lymph node through local administration of CpG-B and GM-CSF: recruitment and activation of BDCA3/CD141(+) dendritic cells and enhanced cross-presentation. Cancer Immunol Res. 2015;3:495–505. https://doi.org/10.1158/2326-6066.CIR-14-0165.CrossRefPubMed

46.

Koster BD, van den Hout MFCM, Sluijter BJR, Molenkamp BG, Vuylsteke RJCLM, Baars A, et al. Local adjuvant treatment with low-dose CpG-B offers durable protection against disease recurrence in clinical stage I-II melanoma: data from two randomized phase II trials. Clin Cancer Res. 2017;23:5679–86.CrossRefPubMed

Title: ‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment
Authors: J. Rotman
C. H. Mom
E. S. Jordanova
T. D. de Gruijl
G. G. Kenter
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-018-4764-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Discussion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2018

Carbonic anhydrase related protein expression in astrocytomas and oligodendroglial tumors

Cancer survivors’ needs during various treatment phases after multimodal treatment for colon cancer - is there a role for eHealth?

MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT

Development of a computational promoter with highly efficient expression in tumors

Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis

MGAT1 is a novel transcriptional target of Wnt/β-catenin signaling pathway

Keynote webinar | Spotlight on antibody–drug conjugates in cancer